US20010001824A1 - Chamber for applying therapeutic substances to an implantable device - Google Patents

Chamber for applying therapeutic substances to an implantable device Download PDF

Info

Publication number
US20010001824A1
US20010001824A1 US09754619 US75461901A US2001001824A1 US 20010001824 A1 US20010001824 A1 US 20010001824A1 US 09754619 US09754619 US 09754619 US 75461901 A US75461901 A US 75461901A US 2001001824 A1 US2001001824 A1 US 2001001824A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
chamber
therapeutic substance
stent
prosthesis
balloon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09754619
Other versions
US6346110B2 (en )
Inventor
Steven Wu
Original Assignee
Wu Steven Z.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/04Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06Blood vessels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067Means for introducing or releasing pharmaceutical products into the body
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B05SPRAYING OR ATOMISING IN GENERAL; APPLYING LIQUIDS OR OTHER FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05CAPPARATUS FOR APPLYING LIQUIDS OR OTHER FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05C3/00Apparatus in which the work is brought into contact with a bulk quantity of liquid or other fluent material
    • B05C3/20Apparatus in which the work is brought into contact with a bulk quantity of liquid or other fluent material for applying liquid or other fluent material only at particular parts of the work

Abstract

A chamber is provided that allows a user to medicate an implantable prosthesis such as a stent. The implantable prosthesis is capable of securing a therapeutic substance and subsequently delivering the therapeutic substance to local tissues. The chamber allows a user to medicate the prosthesis subsequent to the sterilization process and immediately prior to the implantation procedure. The chamber includes a hollow body defining a chamber cavity that encapsulates the prosthesis crimped on a balloon of a catheter assembly. The chamber is removably mounted on the catheter assembly. A user can supply therapeutic substances into the chamber and allow the therapeutic substances to be secured by the prosthesis. After allowing the prosthesis to be soaked by the therapeutic substances for a predetermined amount of time, the chamber is removed and the prosthesis is ready for the implantation procedure.

Description

    BACKGROUND OF THE INVENTION
  • 1. Field of the Invention [0001]
  • This invention generally relates to implantable devices, such as an expandable intraluminal prosthesis commonly known as stents. More particularly, this invention relates to a structures and techniques for applying therapeutic substances to an implantable device in association with the implantation procedure. [0002]
  • 2. Description of the Related Art [0003]
  • Percutaneous transluminal coronary angioplasty (PTCA) is a procedure for treating heart disease. A catheter assembly having a balloon portion is introduced into the cardiovascular system of a patient via the brachial or femoral artery. The catheter assembly is advanced through the coronary vasculature until the balloon portion is positioned across the occlusive lesion. Once in position across the lesion, the balloon is inflated to a predetermined size to radially compress the atherosclerotic plaque of the lesion against the inner wall of the artery to dilate the lumen. The balloon is then deflated to a smaller profile to allow the catheter to be withdrawn from the patient's vasculature. [0004]
  • A problem associated with the above procedure includes formation of intimal flaps or torn arterial linings which can collapse and occlude the conduit after the balloon is deflated. Moreover, thrombosis and restenosis of the artery may develop over several months after the procedure, which may require another angioplasty procedure or a surgical by-pass operation. To reduce the partial or total occlusion of the artery by the collapse of arterial lining and to reduce the chance of the development of thrombosis and restenosis, an expandable intraluminal prosthesis, an example of which includes a stent, is implanted in the lumen to maintain the vascular patency. A well known procedure for delivering the stent to the diseased site includes crimping a compressed stent about the balloon of the catheter such that when the balloon is inflated, the stent dilates and is disposed within the vasculature. FIG. 1 illustrates an example of the end result, the balloon having been deflated and withdrawn. FIG. 1 shows a stent [0005] 10, generally tubular in shape, in its expanded position, functioning to hold open and, if desired, to expand a segment of an anatomical lumen 12. As best shown by FIG. 1, stent 10 prevents torn or injured arterial lining 14 from occluding lumen 12.
  • In treating the damaged vasculature tissue and to further fight against thrombosis and restenosis, there is a need for administrating therapeutic substances to the treatment site. For example, anticoagulants, antiplatelets and cytostatic agents are commonly used to prevent thrombosis of the coronary lumen, to inhibit development of restenosis, and to reduce post-angioplasty proliferation of the vascular tissue, respectively. To provide an efficacious concentration to the treated site, systemic administration of such medication often produces adverse or toxic side effects for the patient. Local medication delivery is a preferred method of treatment in that smaller total levels of medication are administered in comparison to systemic dosages, but are concentrated at a specific site. Local delivery thus produces fewer side effects and achieves more effective results. One commonly applied technique for the local delivery of the drugs is through the use of medicated stents. Stents that are capable of storing medication and releasing it at the implanted site are well known in the art. A metallic stent coated with a polymeric material which is impregnated with a drug or a combination of drugs is one example. Once the stent is implanted within the lumen, the drug(s) are released from the polymer. U.S. Pat. No. 5,605,696 to Eury et al., U.S. Pat. No. 5,464,650 to Berg et al., and U.S. Pat. No. 5,700,286 to Tartaglia et al. are examples illustrating the use of a polymeric coating for the local delivery of the drug(s). [0006]
  • Sterilization of medicated stents in preparation for stent therapy significantly limits the choice of drugs with which the stent can be medicated. More specifically, stents are sterilized by ethylene oxide (Eto) gas or electron beam radiation. Some therapeutic substances do not tolerate either the Eto or electron beam radiation procedure. Although some therapeutic substances tolerate Eto, Eto is the less preferred method of sterilization for coronary procedures since the procedure leaves an ethylene residue on the stent after sterilization, provoking an inflammatory response. [0007]
  • The available choice of therapeutic substances for medicating stents therefore includes substances that are not adversely affected by electron beam radiation. The selections are limited. Accordingly, it is desirable to medicate the stent subsequent to the sterilization procedure. [0008]
  • Medicated stents also inhibit a treating physician's ability to make an ad hoc selection of most suitable therapeutic substance or combination of therapeutic substances, and dosage for a particular patient. A physician cannot custom treat a stent according to a patient's needs, but rather is limited to selections that are already provided by a biomedical supplier. Accordingly, it is desirable to allow a physician to medicate the stent in accordance with the particular needs of a patient. [0009]
  • Stents are medicated by a biomedical supplier well in advance of the stent therapy procedure and supplied to users in sterile packages. The therapeutic substance concentration that is secured by the stent diminishes during storage in sterile packages due to inevitable diffusion of the substance from the stent. The time lapse between treating a stent with a therapeutic substance and implanting the stent may decrease the therapeutic substance's efficacy or require the package to be discarded if extending beyond the package expiration date. Accordingly, it is desirable to medicate a stent immediately prior to the stent therapy. [0010]
  • SUMMARY OF THE INVENTION
  • In accordance with various aspects of the present invention, a chamber is configured for usage with a catheter to apply one or more therapeutic substances to an implantable device such as a stent after sterilization but before implantation therapy. The chamber is configured to be mounted on a catheter assembly having a balloon portion and a stent crimped or mounted on the balloon portion. The chamber comprises a hollow body defining a chamber cavity, which encapsulates the stent. The chamber includes an inlet duct and an outlet duct which allow a user to supply therapeutic substance(s) into the chamber cavity and to discharge the therapeutic substance(s) out of the chamber cavity. [0011]
  • In one embodiment, the hollow body includes a first end and a second end opposing the first end, the first end having an aperture and a sealing member disposed on a periphery of the aperture. [0012]
  • In another embodiment, the second end additionally has an aperture and a sealing member on a periphery of the aperture. [0013]
  • In another embodiment, the hollow body of the chamber includes an upper chamber body and a lower chamber body. The upper and lower chamber bodies can be releasably secured together to form the chamber cavity. [0014]
  • Another aspect of the present invention is a method of medicating the stent by supplying a therapeutic substance into the chamber cavity wherein the substance is exposed to or soaks the stent. The therapeutic substance is trapped in the chamber cavity and discharged after a predetermined period of time. Alternatively, the therapeutic substance is immediately discharged as it is supplied into the chamber cavity, creating a continuous flow through the chamber cavity. The continuous flow is maintained for a predetermined amount of time. The stent used in conjunction with the chamber of the present invention should be capable of storing or securing the therapeutic substance(s) and releasing the substance(s) at the site of treatment. [0015]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 illustrates an expanded stent within a vessel after withdrawal of a catheter assembly; [0016]
  • FIG. 2 is a prospective view of a catheter assembly having a chamber mounted thereon in accordance with one embodiment of the invention; [0017]
  • FIG. 3 is a cross-sectional view of the chamber, encapsulating a stent crimped on a balloon of the catheter assembly; [0018]
  • FIG. 4 is a prospective view of the chamber in accordance with another embodiment of the present invention; and [0019]
  • FIG. 5 is a side view of the chamber in accordance with another embodiment of the present invention. [0020]
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • Referring to the drawings, wherein similar parts are identified by like reference numeral, FIG. 2 illustrates a chamber [0021] 40 that is configured for usage with a catheter assembly 20. The catheter assembly 20 can be any conventional catheter assembly that is well known and used in a variety of medical procedures such as percutaneous transluminal coronary angioplasty (PTCA), vascular prosthetic implantation, and atherectomy.
  • Catheter assembly [0022] 20 includes catheter tube 22 having a distal end 24 and a balloon 26 incorporated proximal to distal end 24. Balloon 26 is inflatable to dilate from a collapsed configuration to an expanded configuration. Balloon 26 is selectively deflatable after inflation to return to the collapsed configuration. Balloon 26 can be fabricated, for example, from a flexible polymer such as nylon, polyethylene, or polyethylene terephthalate. The illustrative balloon 26 is adapted for inserting and dilating an implantable device or an expandable prosthesis 28 (see FIG. 3), e.g., a stent. The selection of a particular balloon-catheter assembly 20 is not critical so long as the assembly 20 is capable of and suitable for delivering implantable device 28.
  • As further illustrated in FIGS. [0023] 2-5 the chamber 40 is provided that allows a user such as a physician to medicate stent 28 immediately prior to implantation procedure. Chamber 40 is removably mounted on balloon 26 and encapsulates stent 28. Chamber 40 is generally defined by a hollow, tubular body 42 defining a chamber cavity 44. Chamber 40 further has an inlet duct 46 and a pair of outlet ducts 48. Inlet duct 48 and outlet ducts 48 are typically apertures, conduits or tubes expanding out of tubular body 42. Inlet duct 46 and outlet ducts 48 are typically open passageways or closed passageways that are capable of penetration by a syringe. Alternatively, inlet duct 46 and outlet ducts 48 can be open passageways sealed by removable caps (not illustrated). In various embodiments chamber 40 can have any number of inlet ducts 46 and outlet ducts 48 and extend beyond the specific structure shown in FIGS. 2-5. Tubular body 42 has a pair of opposing ends 50 and 52 having apertures 53A and 53B formed therein. A pair of sealing members 54A and 54B, illustratively “O” rings, are disposed about the periphery of apertures 53A and 53B, respectively. Sealing members 54A and 54B seal chamber 40 against balloon 26 and prevent significant leakage of fluids or gases out of chamber cavity 44. Chamber 40 is generally capable of insertion onto and removal from catheter assembly 20 by threading and retracting distal end 24 of catheter assembly 20 through apertures 53A and 53B. Sealing members 54A and 54B facilitate sliding of the chamber 40 onto balloon 26 and off balloon 26 to prevent significant variation or disturbance to the positioning of stent 28 and prevent damage to the structure of stent 28.
  • An alternative embodiment is illustrated in FIG. 4 in which chamber [0024] 40 includes an upper chamber body 58 and a lower chamber body 60 which are configured to mate to form chamber cavity 44. Latching members 62 are disposed about the periphery of upper and lower chamber bodies 58 and 60, and are used to releasably lock upper chamber body 58 against lower chamber body 60. Stent 28 is encapsulated by positioning balloon 26 between upper and lower chamber bodies 58 and 60 and securely mating the upper and lower chamber bodies 58 and 60 to one another. The encapsulation method is more suitable for preventing significant disturbance to the positioning of stent 28 and damage to structure of the stent than the method of sliding chamber 40 on and off balloon 26. Other conventional articles, such as screws, may alternatively be used to secure upper chamber body 58 to lower chamber body 60. A sealing member (not illustrated) may be disposed about lips 64 and 66 of upper and lower chamber bodies 58 and 60 to prevent significant leakage of fluids or gases from chamber cavity 44.
  • Chamber [0025] 40 is fabricated from any suitable material that does not react adversely or erode when in contact with therapeutic substances or the solvents carrying such substances. Alternatively, the inside surfaces of chamber cavity 44 can be coated with a suitable material for preventing pollution or degradation of therapeutic substances that are introduced into chamber cavity 44. By way of example and not limitation, chamber 40 may be fabricated from any suitable polymer, such as a polytetrafluoroethylene or high density polyethylene. Chamber 40 may also be fabricated from a metallic material such as aluminum or stainless steel. It is understood that chamber 40 can be of any suitable size and can have a variety of suitable shapes, other than tubular body 42 illustrated in FIG. 2-5. As further illustrated in FIG. 5, chamber 40 can have a closed end 56 in lieu of aperture 53A of end 50.
  • In an illustrative commercial kit, the catheter assembly [0026] 20 with implantable device 28 (for example, stent) is sterilized and packaged in combination with chamber 40 removably encapsulating the implantable device 28, for usage by a user such as a physician. The user removes the combined catheter assembly 20 and mounted chamber 40 from the sterile commercial kit immediately prior to the implantation therapy and uses chamber 40 to medicate stent 28 according to the individual requirements of the patient. The user then removes chamber 40 from balloon 26, and performs the implantation procedure.
  • In an alternative commercial embodiment, the catheter assembly [0027] 20 and the chamber 40 are packaged in separate sterile kits. A user removes the sterilized catheter assembly 20 and the chamber 40 from respective sterile kits. The user encapsulates balloon 26 within chamber 40 and medicates stent 28. The user then removes chamber 40 from balloon 26 and performs the implantation procedure. In various embodiments, catheter assembly 20 may be provided having stent 28 mounted on the assembly 20, or stent 28 may be provided in a separate sterile kit. In cases with separate packaging for the catheter assembly 20 and stent 28, the user crimps the stent 28 onto the balloon 26 prior to usage.
  • In further additional commercial embodiments, the chamber [0028] 40, catheter assembly 20 and stent 28 may be provided in non-sterile kits in which case all articles are sterilized prior to the treatment of a patient.
  • As described hereinafter with reference to Examples [0029] 1-4, stent 28 is medicated by introducing a solution of a therapeutic substance into chamber 40 encasing stent 28 through inlet duct 46 so that the therapeutic substance is in contact with stent 28. According to a first illustrative technique, the solution is trapped in chamber cavity 44 by closing outlet duct 48. Stent 28 is soaked for a predetermined period of time, then the solution is discharged from chamber cavity 44.
  • Alternatively, the therapeutic solution is introduced to chamber [0030] 40 via inlet duct 46 with outlet duct 48 left open so that the solution continuously flows through chamber cavity 44. The medicated solution simultaneously discharges from outlet duct 48 substantially at the rate the solution is supplied through inlet duct 46. Stent 28 is thus exposed to the continuous flow or soaked by the medicated solution for a predetermined period of time. In some applications a second solution such as a medicated solution, an aqueous solution, water, or the like can be supplied through the chamber 40 following application of the first solution. The type of medicated solution, the number of solutions applied, the dosages, dosage rates, concentrations of the solutions, and the duration of exposure or soaking depend on the type of stent and the therapy applied to the patient. Similarly, the therapy parameters are interrelated so that the dosages, dosage rates, and durations of exposure depend on the therapeutic substances, solvents, duration of the local therapy, rate of release, and the cumulative amount of release that is desired. Correlations and interrelations between therapy parameters are well known in the art and are easily calculated.
  • As discussed in the Background of the Invention, sterilization of a stent after the stent is medicated but before stent therapy limits the choice of drugs with which stent can be medicated since many therapeutic drugs do not tolerate conventional ethylene oxide (Eto) gas or electron beam radiation sterilization procedures. Chamber [0031] 40 advantageously allows a user to change the order of sterilization and medication of a stent so that the stent is first sterilized, then medicated, before usage as an implant. The chamber 40 thus expands the selection of therapeutic substances that are available to the physician to substances that are adversely affected by electron beam radiation. Chamber 40 also allows the physician to treat a subject more effectively. In other words, the physician can select on an ad hoc basis the most suitable therapeutic substance or combination of substances and the dosage(s) in accordance with the particular needs of a subject.
  • Examples in the expanded list of therapeutic substances or agents used in conjunction with chamber [0032] 40 include, but are not limited to, antineoplastic, anti-inflammatory, antiplatelet, anticoagulant, fribrinolytic, thrombin inhibitor, antimitotic, and antiproliferative substances. Examples of antineoplastics include paclitaxel and docetaxel. Examples of antiplatelets, anticoagulants, fribrinolytics, and thrombin inhibitors include sodium heparin, low molecular weight heparin, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antibody, recombinant hirudin, thrombin inhibitor (available from Biogen), and 7E-3B® (an antiplatelet drug from Centocore). Examples of suitable antimitotic agents include methotrexate, azathioprine, vincristine, vinblastine, flurouracil, adriamycin, and mutamycin. Examples of suitable cytostatic or antiproliferative agents include angiopeptin (a somatostatin analogue from Ibsen), angiotensin converting enzyme inhibitors such as Captopril® (available from Squibb), Cilazapril® (available from Hofman-LaRoche), or Lisinopril® (available from Merck); calcium channel blockers (such as Nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonist, Lovastatin® (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug from Merck), monoclonal antibodies (such as PDGF receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitor (available form Glazo), Seramin (a PDGF antagonist), serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide. Other therapeutic substances or agents which may be appropriate include alpha-interferon, genetically engineered epithelial cells, and dexamethasone. While the foregoing therapeutic substances or agents are well known for their preventative and treatment purposes, they are provided by way of example and are not meant to be limiting. Other therapeutic substances which are currently available or may be developed are equally applicable for use with the present invention. The treatment of patients using the above mentioned medicines is well known in the art.
  • Referring to FIG. 3, stent [0033] 28 is crimped on balloon 26 in a compressed configuration. Stent 28 is defined by a plurality of radially expandable cylindrical elements 30 disposed coaxially and interconnected by connecting elements 32. Connecting elements 32 are disposed between adjacent cylindrical elements 30. Cylindrical 30 and connecting 32 elements can be fabricated from a metallic material or an alloy such as stainless steel (e.g., 316L), “MP35N,” “MP20N,” tantalum, nickel-titanium alloy (commercially available as Nitinol™), platinum-iridium alloy, gold, magnesium, or combinations thereof. “MP35N” and “MP20N” are trade names for alloys of cobalt, nickel, chromium and molybdenum available from standard Press Steel Co., Jenkintown, Pa. “MP35N” consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum. “MP20N” consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum. It is understood, however, that the underlying structure of stent 28 can be virtually any stent design. It is further understood the aforementioned list is merely an exemplary list of materials that can be used and that other materials, such as polymeric materials, have been proven to function effectively. Examples of polymeric material include, poly(ethylene terephthalate), polyacetal, poly(lactic acid), and poly(ethylene oxide)/poly(butylene terephthalate) copolymer.
  • A suitable stent [0034] 28 used in conjunction with chamber 40 is a stent that stores or secures therapeutic substance(s) and allow the substance(s) to be released at the implanted site for a predetermined duration of time. Stents that are capable of being impregnated with or securing therapeutic substance(s) and locally releasing such substance(s) for a predetermined duration of time are illustrated by the following set of examples by way of example only and not by way of limitation. The structure of the stents, the materials used, and the method of storing or securing therapeutic substance(s) on to the stent should not be construed to limit the scope of the invention.
  • EXAMPLE 1
  • An illustrative Stent [0035] 28 is a bare metallic stent such that the metallic substrate is capable of absorbing or attaching to therapeutic substance(s). To medicate stent 28, the metallic substrate of stent 28 is exposed to or soaked with a solvent carrying a therapeutic substance by supplying the solution through inlet duct 46 of chamber 40. The therapeutic substance is dispersed throughout the solvent in a true solution with the solvent and not dispersed in fine particles. The medicated solution absorbs or attaches to the metallic substrate and is released in vivo after stent 28 is implanted. A suitable exposure of the metallic substrate to the solvent does not adversely alter the composition or characteristics of the therapeutic substance. Examples of some suitable combinations of metallic substrates, solvents, and therapeutic substances are set forth in Table I. Table I is an exemplary list of a few suitable combinations, and it is understood that many other combinations can be practiced with chamber 40.
    TABLE I
    Metallic Substrate Solvent Therapeutic Substance
    Stainless Steel (e.g., 316L) ethanol dexamethasone
    Stainless Steel (e.g., 316L) chloroform dexamethasone
    Stainless Steel (e.g., 316L) methyl alcohol taxol
    Nitinol ™ water aspirin
    Nitinol ™ water heparin
  • Therapeutic parameters such as dosages, dosage rates, concentration of the solution, and the duration of exposure depend on various factors including metallic substrate type, particular selected therapeutic substance, particular selected solvent, and the duration of the local release, the cumulative amount of release, and the rate of release that is desired. Correlations and interrelations between therapeutic parameters are well known in the art and are easily calculated. [0036]
  • EXAMPLE 2
  • For some illustrative catheters the metallic material from which stent [0037] 28 is made include a plurality of porous cavities, as disclosed in U.S. Pat. No. 5,843,172 to John Y. Yan, which is incorporated herein by reference in its entirety. The porous cavities of stent 28 are typically formed by sintering the stent material from metallic particles, filaments, fibers or other materials as disclosed in Yan. As a result, a therapeutic substance is loaded directly into the cavities. To load the cavities, stent 28 is soaked by supplying a solvent carrying a therapeutic substance into chamber cavity 44. The substance is dispersed throughout the chamber cavity 44 either in a true solution with the solvent, or dispersed in fine particles in the solvent. The medicated solute or the fine particles impregnate the cavities and are generally released in vivo over a desired period of time. Therapeutic parameters such as dosages, dosage rates, concentration of the solution, size of the particles if not in true solution, and the duration of exposure depend on various factors including size of the cavities, particular selected therapeutic substance, particular selected solvent, and the duration of the local release, the cumulative amount of release, and the rate of release that is desired. Correlations and interrelations between therapeutic parameters are well known in the art and are easily calculated.
  • EXAMPLE 3
  • In another example, stent [0038] 28 has a coating of a polymeric material capable of carrying and releasing the therapeutic substance. Polymeric material for carrying therapeutic substances are well known and practiced in the art. In order to medicate stent 28, chamber 40 is used to soak the polymeric coating with a solvent carrying a therapeutic substance. The substance is dissolved throughout the solvent to form a true solution with the solvent. The medicated solute absorbs into the micropores or matrices of the polymer and is capable of being released, in situ, over a predetermined period of time. The polymeric material is preferably a biocompatible material such as one or more polymers which, in the amounts employed, are non-toxic, non-inflammatory, chemically inert, and substantially non-immunogenetic. The polymer may either be bioabsorbable or biostable. A bioabsorbable polymer biodegrades or breaks down in the body and does not remain present long after implantation to cause any adverse local response. Bioabsorbable polymers are gradually absorbed or eliminated by the body by hydrolysis, metabolic process, bulk or surface erosion, or similar processes. Examples of bioabsorbable, biodegradable materials include, but are not limited to, polycaprolactone (PCL), poly-D, L-lactic acid (DL-PLA), poly-L-lactic acid (L-PLA), poly(lactide-co-glycolide), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(glycolic acid-cotrimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly (amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), copoly(ether-esters), polyalkylene oxalates, polyphosphazenes, polyiminocarbonates, and aliphatic polycarbonates. Biomolecules such as fibrin, fibrinogen, cellulose, starch, and collagen may also be suitable. Examples of biostable polymers include Parylene®, Parylast®, polyurethane (e.g., segmented polyurethanes such as Biospan®), polyethylene, polyethlyene teraphthalate, ethylene vinyl acetate, silicone and polyethylene oxide. It is essential for the polymeric coating not to dissolve when exposed to the solvent. It is also essential for the exposure of the solvent to the polymer not to adversely alter the therapeutic substance's composition or characteristic. Examples of suitable combinations of polymers, solvents, and therapeutic substances are depicted in Table II. Table II is an exemplary list of a few suitable combinations, and it is understood that many other combinations can be practiced with chamber 40.
    TABLE II
    Polymer Solvent Therapeutic Substance
    paralene water IIb/Illa receptor antibody
    (e.g., ReoPro ®)
    silicone chloroform dexamethasone
    silicone ethanol dexamethasone
    silicone chloroform aspirin
    urethane none liquid form Vitamin E
    urethane dimethylsulfoxide (DMSO) vinblastine
  • Therapeutic parameters such as dosages, dosage rates, concentration of the solution, and the duration of exposure depend on various factors including particular selected polymeric coating, particular selected therapeutic substance, particular selected solvent, and the duration of the local release, the cumulative amount of release, and the rate of release that is desired. Correlations and interrelations between therapeutic parameters are well known in the art and are easily calculated. [0039]
  • EXAMPLE 4
  • For polymeric carriers that are impregnated with a therapeutic substance by a simple soaking operation, the duration of release of the therapeutic substance from the polymeric carrier is substantially equal to the time of exposure of the carrier. For example, a two (2) hour soaking of the polymeric carrier has an equivalent two (2) hour duration of in vivo release. [0040]
  • Typically it is advantageous to prolong the duration of in vivo release to days or weeks, but impracticable and undesirable to use chamber [0041] 40 to soak the polymeric carrier with a medicated solution for such time durations. Accordingly, polymers that are susceptible to swell loading or post-loading are advantageously used to increase the release duration. Swell loading or post-loading are well understood and practiced in the art. In a conventional and well known swell loading method, the polymeric carrier is soaked with a therapeutic substance/solvent solution. A suitable solvent is capable of not only carrying (i.e., not adversely affecting the therapeutic substance's characteristics or chemically altering the substance, and the substance should be capable of dissolving in the solvent) the therapeutic substance, but causing the polymer to swell. Optimal loading of the substance is obtained when the substance is highly soluble in the solvent, for example, when the substance is saturated in the solvent. Super-saturation of the solute is not desirable. Swelling of the polymeric carrier causes a higher quantity of the substance solute to diffuse into the matrices of the polymer in a shorter duration of time than by simply soaking a polymer that is not susceptible to swell loading.
  • Swell loading of a polymeric carrier using chamber [0042] 40 involves supplying a solution carrying a therapeutic substance into chamber cavity 44. The solution can be either an aqueous solution or a non-aqueous solution. A solvent which causes the greatest amount of swelling with the particular polymer is most advantageously chosen. After soaking stent 28 with either an aqueous or a non-aqueous solution, chamber 40 is removed and stent 28 is rapidly dried for example by exposure to mild heat for several minutes. The rapid removal or drying of the solvent from the polymeric carrier causes the polymer to collapse, trapping a high concentration of the substance into the polymer's matrices.
  • Alternatively, if a non-aqueous solution is used, water can be supplied into chamber cavity [0043] 44 to rinse the polymeric carrier. Water precipitates the therapeutic substance and collapses the polymer. If water is used to collapse the polymer, a water-miscible solvent is generally most suitable. A suitable polymer does not dissolve when exposed to the solvent. A suitable combination of solvent and polymer does not chemically alter the composition of the substance or adversely affect the substance characteristics. Examples of some suitable combinations of polymers, solvents, and therapeutic substances are set forth in Table III. Table III is an exemplary list of a few suitable combinations. Other combinations are also suitable for usage with chamber 40.
    TABLE III
    Polymer Solvent Therapeutic Substance
    TecoGel ® water IIb/IIIa receptor antibody
    (manufactured by Thermedics) (e.g., ReoPro ®)
    Tecophilic ® water aspirin
    (manufactured by Thermedics)
    Tecophilic ® chloroform dexamethasone
    polyvinyl alcohol chloroform dexamethasone
    polyvinyl alcohol water heparin
  • Therapeutic parameters such as dosages, dosage rates, concentration of the solution, and the duration of exposure depend on various factors including particular selected polymer, particular selected therapeutic substance, particular selected solvent, and the duration of the local release, the cumulative amount of release, and the rate of release that is desired. Correlations and interrelations between therapeutic parameters are well known in the art and are easily calculated. [0044]
  • While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from this invention in its broader aspects and, therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of this invention. [0045]

Claims (29)

    What is claimed is:
  1. 1. A chamber which allows a user to medicate implantable devices, comprising:
    (a) a hollow body defining a chamber cavity, said chamber cavity is configured to encapsulate an implantable device; and
    (b) an inlet disposed in said hollow body, said inlet allows a user to supply a therapeutic substance into said chamber cavity, wherein said therapeutic substance contacts said implantable device.
  2. 2. The chamber of
    claim 1
    , additionally comprising an outlet disposed in said hollow body, said outlet allows said therapeutic substance to be discharged out of said chamber cavity.
  3. 3. The chamber of
    claim 1
    , wherein said hollow body comprises a first end and a second end opposing said first end, said first end having an aperture and a sealing member disposed on a periphery of said aperture.
  4. 4. The chamber of
    claim 1
    , wherein said hollow body comprises a pair of opposing ends, each of said ends having an aperture and a sealing member disposed on a periphery of said aperture.
  5. 5. The chamber of
    claim 1
    , wherein said implantable device is a stent.
  6. 6. The chamber of
    claim 1
    , wherein said hollow body comprises an upper chamber body and a lower chamber body, said chamber bodies configured to releasably secure together to form said chamber cavity.
  7. 7. The chamber of
    claim 1
    , wherein said therapeutic substance is selected from a group of antineoplastic, antiplatelet, anticoagulant, fribrinolytic, antimitotic, thrombin inhibitor, antiinflammatory and antiproliferative substances.
  8. 8. The chamber of
    claim 1
    , wherein said chamber is configured to removably encapsulate a balloon portion of a catheter assembly.
  9. 9. A medical assembly, comprising:
    (a) a catheter assembly having a balloon;
    (b) a stent mounted on said balloon, said stent is capable of securing a therapeutic substance when exposed to said therapeutic substance and said stent is capable of releasing said therapeutic substance after said stent has been implanted in a subject.
    (c) a chamber encapsulating said stent, said chamber allows a user to expose said therapeutic substance to said stent.
  10. 10. The medical assembly of
    claim 9
    , wherein said therapeutic substance is added to a fluid and supplied into said chamber, wherein said fluid soaks said stent.
  11. 11. The medical assembly of
    claim 9
    , wherein said stent is coated with a polymeric material capable of being impregnated with said therapeutic substance.
  12. 12. The medical assembly of
    claim 11
    , wherein said polymeric material swells when in contact with a solvent carrying said therapeutic substance and collapses when said solvent is significantly removed from said polymeric material.
  13. 13. The medical assembly of
    claim 9
    , wherein said chamber comprises:
    (a) a hollow body defining a chamber cavity, said hollow body having a first end and an aperture formed on said first end;
    (b) a sealing member disposed on a periphery on said aperture, said sealing member is compressed against said catheter assembly and prevents any significant leakage of fluids or gases out of said chamber cavity from said aperture;
    (c) an inlet disposed in said hollow body for allowing a user to supply said therapeutic substance into said chamber cavity; and
    (d) an outlet disposed in said hollow body for allowing a user to discharge said therapeutic substance from said chamber cavity.
  14. 14. The medical assembly of
    claim 13
    , wherein said hollow body comprises a second end opposing said first end, said second end having an aperture formed therein and a sealing member disposed on a periphery of said aperture of said second end, said sealing member of said second end is compressed against said catheter assembly and prevents any significant leakage of fluids or gases out of said chamber cavity from said aperture of said second end.
  15. 15. The medical assembly of
    claim 13
    , wherein said hollow body comprises an upper chamber body and a lower chamber body, said chamber bodies are configured to releasably secure together to form said chamber cavity.
  16. 16. The medical assembly of
    claim 9
    , wherein said therapeutic substance is selected from a group of antineoplastic, antiinflammatory, antiplatelet, anticoagulant, fribrinolytic, antimitotic, thrombin inhibitor, and antiproliferative substances.
  17. 17. A method of medicating a prosthesis prior to implanting said prosthesis in a subject, comprising the acts of:
    (a) providing a catheter assembly, a balloon disposed on said catheter assembly, a prosthesis mounted on said balloon, and a chamber encapsulating said prosthesis; and
    (b) supplying a therapeutic substance into said chamber, wherein said therapeutic substance is secured by said prosthesis and is capable of being released after said prosthesis is implanted in a subject.
  18. 18. The method of
    claim 17
    , additionally comprising the act of sterilizing said prosthesis prior to said act of supplying said therapeutic substance into said chamber.
  19. 19. The method of
    claim 18
    , wherein said act of sterilizing is performed by electron beam radiation.
  20. 20. The method of
    claim 17
    , wherein said act of providing comprises removing said catheter assembly having said balloon, said prosthesis mounted on said balloon, and said chamber encapsulating said prosthesis from a package.
  21. 21. The method of
    claim 17
    , wherein said act of providing comprises removing said catheter assembly having said balloon and said prosthesis mounted on said balloon from a first package, removing said chamber from a second package, and mounting said chamber on said catheter assembly.
  22. 22. The method of
    claim 17
    , wherein said act of providing comprises removing said catheter assembly having said balloon from a first package, removing said prosthesis from a second package, crimping said prosthesis on said balloon, removing said chamber from a third package, and mounting said chamber on said catheter assembly.
  23. 23. The method of
    claim 17
    , wherein said act of supplying a therapeutic substance into said chamber comprises adding said therapeutic substance to a fluid and supplying said fluid into said chamber.
  24. 24. The method of
    claim 17
    , wherein during said act of supplying, said therapeutic substance is not discharged from said chamber as it is being supplied into said chamber.
  25. 25. The method of
    claim 24
    , additionally comprising the act of discharging said therapeutic substance from said chamber after a predetermined period of time.
  26. 26. The method of
    claim 17
    , wherein during said act of supplying, said therapeutic substance is discharged out of said chamber as it is being supplied into said chamber, said therapeutic substance is supplied for a predetermined period of time.
  27. 27. The method of
    claim 17
    , additionally including the act of removing said chamber from said catheter assembly subsequent to exposing said therapeutic substance to said prosthesis for a predetermined period of time.
  28. 28. The method of
    claim 17
    , additionally including the act of implanting said prosthesis in a subject.
  29. 29. The method of
    claim 17
    , wherein said therapeutic substance is selected from a group of antineoplastic, antiplatelet, anticoagulant, fribrinolytic, antimitotic, thrombin inhibitor, antiinflammatory and antiproliferative substances.
US09754619 1999-10-04 2001-01-03 Chamber for applying therapeutic substances to an implantable device Active US6346110B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09411029 US6203551B1 (en) 1999-10-04 1999-10-04 Chamber for applying therapeutic substances to an implant device
US09754619 US6346110B2 (en) 1999-10-04 2001-01-03 Chamber for applying therapeutic substances to an implantable device

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09754619 US6346110B2 (en) 1999-10-04 2001-01-03 Chamber for applying therapeutic substances to an implantable device

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09411029 Division US6203551B1 (en) 1999-10-04 1999-10-04 Chamber for applying therapeutic substances to an implant device

Publications (2)

Publication Number Publication Date
US20010001824A1 true true US20010001824A1 (en) 2001-05-24
US6346110B2 US6346110B2 (en) 2002-02-12

Family

ID=23627266

Family Applications (2)

Application Number Title Priority Date Filing Date
US09411029 Active US6203551B1 (en) 1999-10-04 1999-10-04 Chamber for applying therapeutic substances to an implant device
US09754619 Active US6346110B2 (en) 1999-10-04 2001-01-03 Chamber for applying therapeutic substances to an implantable device

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09411029 Active US6203551B1 (en) 1999-10-04 1999-10-04 Chamber for applying therapeutic substances to an implant device

Country Status (2)

Country Link
US (2) US6203551B1 (en)
WO (1) WO2001024734A1 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040098118A1 (en) * 2002-09-26 2004-05-20 Endovascular Devices, Inc. Apparatus and method for delivery of mitomycin through an eluting biocompatible implantable medical device
US20040215347A1 (en) * 2003-04-25 2004-10-28 Michael Hayes Method and apparatus for automated handling of medical devices during manufacture
US20050158449A1 (en) * 2002-09-27 2005-07-21 Chappa Ralph A. Method and apparatus for coating of substrates
US20060088653A1 (en) * 2004-10-27 2006-04-27 Chappa Ralph A Method and apparatus for coating of substrates
US20060165872A1 (en) * 2002-09-27 2006-07-27 Chappa Ralph A Advanced coating apparatus and method
USRE40722E1 (en) 2002-09-27 2009-06-09 Surmodics, Inc. Method and apparatus for coating of substrates
US20090234428A1 (en) * 2004-06-28 2009-09-17 Xtent, Inc. Devices and methods for controlling expandable prostheses during deployment
US20110022148A1 (en) * 2007-02-20 2011-01-27 Xtent, Inc. Thermo-mechanically controlled implants and methods of use
US20110093056A1 (en) * 2006-06-02 2011-04-21 Xtent, Inc. Use of Plasma in Formation of Biodegradable Stent Coating
US8585747B2 (en) 2003-12-23 2013-11-19 J.W. Medical Systems Ltd. Devices and methods for controlling and indicating the length of an interventional element
US8652198B2 (en) 2006-03-20 2014-02-18 J.W. Medical Systems Ltd. Apparatus and methods for deployment of linked prosthetic segments
US8702781B2 (en) 2001-12-03 2014-04-22 J.W. Medical Systems Ltd. Apparatus and methods for delivery of multiple distributed stents
US8956398B2 (en) 2001-12-03 2015-02-17 J.W. Medical Systems Ltd. Custom length stent apparatus
US9101503B2 (en) 2008-03-06 2015-08-11 J.W. Medical Systems Ltd. Apparatus having variable strut length and methods of use
US9283350B2 (en) 2012-12-07 2016-03-15 Surmodics, Inc. Coating apparatus and methods
US9308355B2 (en) 2012-06-01 2016-04-12 Surmodies, Inc. Apparatus and methods for coating medical devices
US9339404B2 (en) 2007-03-22 2016-05-17 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
US9364349B2 (en) 2008-04-24 2016-06-14 Surmodics, Inc. Coating application system with shaped mandrel
US9700448B2 (en) 2004-06-28 2017-07-11 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices

Families Citing this family (244)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7682647B2 (en) * 1999-09-03 2010-03-23 Advanced Cardiovascular Systems, Inc. Thermal treatment of a drug eluting implantable medical device
US6217610B1 (en) * 1994-07-29 2001-04-17 Edwards Lifesciences Corporation Expandable annuloplasty ring
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6306166B1 (en) * 1997-08-13 2001-10-23 Scimed Life Systems, Inc. Loading and release of water-insoluble drugs
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US20050238686A1 (en) * 1999-12-23 2005-10-27 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US7807211B2 (en) * 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
US8435550B2 (en) 2002-12-16 2013-05-07 Abbot Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
CA2402949C (en) * 2000-03-18 2009-09-08 Polyzenix Gmbh Polyphosphazene derivatives having bacterial resistance and use thereof
DE10191512D2 (en) * 2000-04-11 2003-03-13 Univ Heidelberg Sheaths and films of poly-tri-fluoro-Ethoxypolyphosphazen
US7682648B1 (en) 2000-05-31 2010-03-23 Advanced Cardiovascular Systems, Inc. Methods for forming polymeric coatings on stents
US6723373B1 (en) * 2000-06-16 2004-04-20 Cordis Corporation Device and process for coating stents
EP1299590A2 (en) * 2000-06-29 2003-04-09 Johnson & Johnson Consumer Companies, Inc. Electrostatic impregnation of powders on substrates
US6555157B1 (en) * 2000-07-25 2003-04-29 Advanced Cardiovascular Systems, Inc. Method for coating an implantable device and system for performing the method
US6451373B1 (en) * 2000-08-04 2002-09-17 Advanced Cardiovascular Systems, Inc. Method of forming a therapeutic coating onto a surface of an implantable prosthesis
EP1179353A1 (en) * 2000-08-11 2002-02-13 B. Braun Melsungen Ag Antithrombogenic implants with coating of polyphosphazenes and a pharmacologically active agent
US20090004240A1 (en) * 2000-08-11 2009-01-01 Celonova Biosciences, Inc. Implants with a phosphazene-containing coating
US6953560B1 (en) * 2000-09-28 2005-10-11 Advanced Cardiovascular Systems, Inc. Barriers for polymer-coated implantable medical devices and methods for making the same
US6783793B1 (en) * 2000-10-26 2004-08-31 Advanced Cardiovascular Systems, Inc. Selective coating of medical devices
US7807210B1 (en) * 2000-10-31 2010-10-05 Advanced Cardiovascular Systems, Inc. Hemocompatible polymers on hydrophobic porous polymers
US6824559B2 (en) * 2000-12-22 2004-11-30 Advanced Cardiovascular Systems, Inc. Ethylene-carboxyl copolymers as drug delivery matrices
US6503280B2 (en) * 2000-12-26 2003-01-07 John A. Repicci Prosthetic knee and method of inserting
US6663662B2 (en) * 2000-12-28 2003-12-16 Advanced Cardiovascular Systems, Inc. Diffusion barrier layer for implantable devices
US9080146B2 (en) * 2001-01-11 2015-07-14 Celonova Biosciences, Inc. Substrates containing polyphosphazene as matrices and substrates containing polyphosphazene with a micro-structured surface
WO2002065946A1 (en) * 2001-02-23 2002-08-29 Angiogene Inc. Apparatus for loading a therapeutic agent onto an endovascular device
DE10115740A1 (en) * 2001-03-26 2002-10-02 Ulrich Speck Preparation for the prophylaxis of restenosis
US6780424B2 (en) * 2001-03-30 2004-08-24 Charles David Claude Controlled morphologies in polymer drug for release of drugs from polymer films
US7056967B2 (en) * 2001-04-10 2006-06-06 Ciba Specialty Chemicals Corporation Stabilized medium and high voltage cable insulation composition
US6764505B1 (en) * 2001-04-12 2004-07-20 Advanced Cardiovascular Systems, Inc. Variable surface area stent
US6712845B2 (en) * 2001-04-24 2004-03-30 Advanced Cardiovascular Systems, Inc. Coating for a stent and a method of forming the same
US6656506B1 (en) * 2001-05-09 2003-12-02 Advanced Cardiovascular Systems, Inc. Microparticle coated medical device
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US6743462B1 (en) 2001-05-31 2004-06-01 Advanced Cardiovascular Systems, Inc. Apparatus and method for coating implantable devices
US7862495B2 (en) * 2001-05-31 2011-01-04 Advanced Cardiovascular Systems, Inc. Radiation or drug delivery source with activity gradient to minimize edge effects
US20030044514A1 (en) * 2001-06-13 2003-03-06 Richard Robert E. Using supercritical fluids to infuse therapeutic on a medical device
US7247313B2 (en) * 2001-06-27 2007-07-24 Advanced Cardiovascular Systems, Inc. Polyacrylates coatings for implantable medical devices
US6695920B1 (en) * 2001-06-27 2004-02-24 Advanced Cardiovascular Systems, Inc. Mandrel for supporting a stent and a method of using the mandrel to coat a stent
US7175873B1 (en) 2001-06-27 2007-02-13 Advanced Cardiovascular Systems, Inc. Rate limiting barriers for implantable devices and methods for fabrication thereof
US7622146B2 (en) * 2002-07-18 2009-11-24 Advanced Cardiovascular Systems, Inc. Rate limiting barriers for implantable devices and methods for fabrication thereof
US8741378B1 (en) 2001-06-27 2014-06-03 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device
US6656216B1 (en) * 2001-06-29 2003-12-02 Advanced Cardiovascular Systems, Inc. Composite stent with regioselective material
US7682669B1 (en) 2001-07-30 2010-03-23 Advanced Cardiovascular Systems, Inc. Methods for covalently immobilizing anti-thrombogenic material into a coating on a medical device
DE50208282D1 (en) * 2001-08-17 2006-11-09 Polyzenix Gmbh Device on the basis of nitinol with polyphosphazenüberzug
US8303651B1 (en) * 2001-09-07 2012-11-06 Advanced Cardiovascular Systems, Inc. Polymeric coating for reducing the rate of release of a therapeutic substance from a stent
US20030050648A1 (en) * 2001-09-11 2003-03-13 Spiration, Inc. Removable lung reduction devices, systems, and methods
US7989018B2 (en) * 2001-09-17 2011-08-02 Advanced Cardiovascular Systems, Inc. Fluid treatment of a polymeric coating on an implantable medical device
US6753071B1 (en) * 2001-09-27 2004-06-22 Advanced Cardiovascular Systems, Inc. Rate-reducing membrane for release of an agent
US7223282B1 (en) 2001-09-27 2007-05-29 Advanced Cardiovascular Systems, Inc. Remote activation of an implantable device
US6592594B2 (en) 2001-10-25 2003-07-15 Spiration, Inc. Bronchial obstruction device deployment system and method
US7150853B2 (en) * 2001-11-01 2006-12-19 Advanced Cardiovascular Systems, Inc. Method of sterilizing a medical device
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
US6517889B1 (en) 2001-11-26 2003-02-11 Swaminathan Jayaraman Process for coating a surface of a stent
US6709514B1 (en) * 2001-12-28 2004-03-23 Advanced Cardiovascular Systems, Inc. Rotary coating apparatus for coating implantable medical devices
US20030154988A1 (en) * 2002-02-21 2003-08-21 Spiration, Inc. Intra-bronchial device that provides a medicant intra-bronchially to the patient
US6929637B2 (en) * 2002-02-21 2005-08-16 Spiration, Inc. Device and method for intra-bronchial provision of a therapeutic agent
EP2308861B1 (en) 2002-03-08 2017-03-01 Eisai R&D Management Co., Ltd. Macrocyclic compounds useful as pharmaceuticals
US7919075B1 (en) 2002-03-20 2011-04-05 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices
US20030181922A1 (en) * 2002-03-20 2003-09-25 Spiration, Inc. Removable anchored lung volume reduction devices and methods
KR101208266B1 (en) 2002-03-22 2012-12-05 에자이 알앤드디 매니지먼트 가부시키가이샤 Hemiasterlin derivatives and uses thereof
US20070032853A1 (en) * 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7048962B2 (en) * 2002-05-02 2006-05-23 Labcoat, Ltd. Stent coating device
US7709048B2 (en) * 2002-05-02 2010-05-04 Labcoat, Ltd. Method and apparatus for coating a medical device
US6645547B1 (en) 2002-05-02 2003-11-11 Labcoat Ltd. Stent coating device
US20030212412A1 (en) * 2002-05-09 2003-11-13 Spiration, Inc. Intra-bronchial obstructing device that permits mucus transport
US20030216769A1 (en) * 2002-05-17 2003-11-20 Dillard David H. Removable anchored lung volume reduction devices and methods
WO2003096932A1 (en) * 2002-05-17 2003-11-27 Bionethos Holding Gmbh Medical device for the treatment of a body vessel or another tubular structure in the body
US7217426B1 (en) 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
US7056523B1 (en) 2002-06-21 2006-06-06 Advanced Cardiovascular Systems, Inc. Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine
US7396539B1 (en) * 2002-06-21 2008-07-08 Advanced Cardiovascular Systems, Inc. Stent coatings with engineered drug release rate
US7033602B1 (en) * 2002-06-21 2006-04-25 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of coating implantable medical devices
US7794743B2 (en) * 2002-06-21 2010-09-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US20080138377A1 (en) * 2002-07-05 2008-06-12 Celonova Biosciences, Inc. Vasodilator Eluting Luminal Stent Devices With A Specific Polyphosphazene Coating and Methods for Their Manufacture and Use
US20080138433A1 (en) * 2002-07-05 2008-06-12 Celonova Biosciences, Inc. Vasodilator eluting blood storage and administration devices with a specific polyphosphazene coating and methods for their manufacture and use
EP1521603B1 (en) * 2002-07-12 2011-01-19 Cook Incorporated Coated medical device
US20040063805A1 (en) * 2002-09-19 2004-04-01 Pacetti Stephen D. Coatings for implantable medical devices and methods for fabrication thereof
DE10244847A1 (en) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck A medical device for drug delivery
US7087263B2 (en) * 2002-10-09 2006-08-08 Advanced Cardiovascular Systems, Inc. Rare limiting barriers for implantable medical devices
US7169178B1 (en) 2002-11-12 2007-01-30 Advanced Cardiovascular Systems, Inc. Stent with drug coating
US6896965B1 (en) * 2002-11-12 2005-05-24 Advanced Cardiovascular Systems, Inc. Rate limiting barriers for implantable devices
US6982004B1 (en) 2002-11-26 2006-01-03 Advanced Cardiovascular Systems, Inc. Electrostatic loading of drugs on implantable medical devices
US7776926B1 (en) * 2002-12-11 2010-08-17 Advanced Cardiovascular Systems, Inc. Biocompatible coating for implantable medical devices
US7758880B2 (en) 2002-12-11 2010-07-20 Advanced Cardiovascular Systems, Inc. Biocompatible polyacrylate compositions for medical applications
US7074276B1 (en) * 2002-12-12 2006-07-11 Advanced Cardiovascular Systems, Inc. Clamp mandrel fixture and a method of using the same to minimize coating defects
US8318235B2 (en) * 2003-01-22 2012-11-27 Cordis Corporation Method for applying drug coating to a medical device in surgeon room
US7563483B2 (en) * 2003-02-26 2009-07-21 Advanced Cardiovascular Systems Inc. Methods for fabricating a coating for implantable medical devices
US6926919B1 (en) 2003-02-26 2005-08-09 Advanced Cardiovascular Systems, Inc. Method for fabricating a coating for a medical device
US7063884B2 (en) * 2003-02-26 2006-06-20 Advanced Cardiovascular Systems, Inc. Stent coating
US20040210248A1 (en) * 2003-03-12 2004-10-21 Spiration, Inc. Apparatus, method and assembly for delivery of intra-bronchial devices
US7100616B2 (en) * 2003-04-08 2006-09-05 Spiration, Inc. Bronchoscopic lung volume reduction method
DE10318803B4 (en) 2003-04-17 2005-07-28 Translumina Gmbh Device for applying active substances to surfaces of medical implants, in particular stents
US8791171B2 (en) * 2003-05-01 2014-07-29 Abbott Cardiovascular Systems Inc. Biodegradable coatings for implantable medical devices
US7279174B2 (en) * 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
US7285304B1 (en) * 2003-06-25 2007-10-23 Advanced Cardiovascular Systems, Inc. Fluid treatment of a polymeric coating on an implantable medical device
US7341630B1 (en) * 2003-06-26 2008-03-11 Advanced Cardiovascular Systems, Inc. Stent coating system
US20050021127A1 (en) * 2003-07-21 2005-01-27 Kawula Paul John Porous glass fused onto stent for drug retention
US7056591B1 (en) * 2003-07-30 2006-06-06 Advanced Cardiovascular Systems, Inc. Hydrophobic biologically absorbable coatings for drug delivery devices and methods for fabricating the same
US7645474B1 (en) 2003-07-31 2010-01-12 Advanced Cardiovascular Systems, Inc. Method and system of purifying polymers for use with implantable medical devices
US7431959B1 (en) * 2003-07-31 2008-10-07 Advanced Cardiovascular Systems Inc. Method and system for irradiation of a drug eluting implantable medical device
US7785512B1 (en) 2003-07-31 2010-08-31 Advanced Cardiovascular Systems, Inc. Method and system of controlled temperature mixing and molding of polymers with active agents for implantable medical devices
WO2005011561A3 (en) 2003-08-04 2005-05-12 Labcoat Ltd Stent coating apparatus and method
US7533671B2 (en) 2003-08-08 2009-05-19 Spiration, Inc. Bronchoscopic repair of air leaks in a lung
US20050048194A1 (en) * 2003-09-02 2005-03-03 Labcoat Ltd. Prosthesis coating decision support system
US20050058768A1 (en) * 2003-09-16 2005-03-17 Eyal Teichman Method for coating prosthetic stents
US7441513B1 (en) 2003-09-26 2008-10-28 Advanced Cardiovascular Systems, Inc. Plasma-generated coating apparatus for medical devices and a method of coating deposition
US7318932B2 (en) * 2003-09-30 2008-01-15 Advanced Cardiovascular Systems, Inc. Coatings for drug delivery devices comprising hydrolitically stable adducts of poly(ethylene-co-vinyl alcohol) and methods for fabricating the same
US7198675B2 (en) 2003-09-30 2007-04-03 Advanced Cardiovascular Systems Stent mandrel fixture and method for selectively coating surfaces of a stent
US7704544B2 (en) * 2003-10-07 2010-04-27 Advanced Cardiovascular Systems, Inc. System and method for coating a tubular implantable medical device
US7329413B1 (en) 2003-11-06 2008-02-12 Advanced Cardiovascular Systems, Inc. Coatings for drug delivery devices having gradient of hydration and methods for fabricating thereof
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
US8192752B2 (en) * 2003-11-21 2012-06-05 Advanced Cardiovascular Systems, Inc. Coatings for implantable devices including biologically erodable polyesters and methods for fabricating the same
US7560492B1 (en) * 2003-11-25 2009-07-14 Advanced Cardiovascular Systems, Inc. Polysulfone block copolymers as drug-eluting coating material
US7807722B2 (en) * 2003-11-26 2010-10-05 Advanced Cardiovascular Systems, Inc. Biobeneficial coating compositions and methods of making and using thereof
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
USRE45744E1 (en) 2003-12-01 2015-10-13 Abbott Cardiovascular Systems Inc. Temperature controlled crimping
US7220816B2 (en) * 2003-12-16 2007-05-22 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on poly(ester amides) and methods for fabricating the same
US7435788B2 (en) * 2003-12-19 2008-10-14 Advanced Cardiovascular Systems, Inc. Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents
US8309112B2 (en) * 2003-12-24 2012-11-13 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same
US8685431B2 (en) * 2004-03-16 2014-04-01 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same
US8551512B2 (en) 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
US20050208093A1 (en) * 2004-03-22 2005-09-22 Thierry Glauser Phosphoryl choline coating compositions
US8778014B1 (en) 2004-03-31 2014-07-15 Advanced Cardiovascular Systems, Inc. Coatings for preventing balloon damage to polymer coated stents
US7820732B2 (en) * 2004-04-30 2010-10-26 Advanced Cardiovascular Systems, Inc. Methods for modulating thermal and mechanical properties of coatings on implantable devices
US8293890B2 (en) 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
US20050265960A1 (en) * 2004-05-26 2005-12-01 Pacetti Stephen D Polymers containing poly(ester amides) and agents for use with medical articles and methods of fabricating the same
US9561309B2 (en) * 2004-05-27 2017-02-07 Advanced Cardiovascular Systems, Inc. Antifouling heparin coatings
US7563780B1 (en) 2004-06-18 2009-07-21 Advanced Cardiovascular Systems, Inc. Heparin prodrugs and drug delivery stents formed therefrom
US20060018948A1 (en) * 2004-06-24 2006-01-26 Guire Patrick E Biodegradable implantable medical devices, methods and systems
US20050287184A1 (en) * 2004-06-29 2005-12-29 Hossainy Syed F A Drug-delivery stent formulations for restenosis and vulnerable plaque
US20060002968A1 (en) * 2004-06-30 2006-01-05 Gordon Stewart Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders
US7758881B2 (en) 2004-06-30 2010-07-20 Advanced Cardiovascular Systems, Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7494665B1 (en) * 2004-07-30 2009-02-24 Advanced Cardiovascular Systems, Inc. Polymers containing siloxane monomers
US8357391B2 (en) 2004-07-30 2013-01-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable devices comprising poly (hydroxy-alkanoates) and diacid linkages
US7648727B2 (en) * 2004-08-26 2010-01-19 Advanced Cardiovascular Systems, Inc. Methods for manufacturing a coated stent-balloon assembly
US7244443B2 (en) * 2004-08-31 2007-07-17 Advanced Cardiovascular Systems, Inc. Polymers of fluorinated monomers and hydrophilic monomers
US8110211B2 (en) * 2004-09-22 2012-02-07 Advanced Cardiovascular Systems, Inc. Medicated coatings for implantable medical devices including polyacrylates
US8312836B2 (en) * 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
WO2006036967A1 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Solubilizing a drug for use in a coating
US8367099B2 (en) * 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
US9801982B2 (en) * 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US8962023B2 (en) * 2004-09-28 2015-02-24 Atrium Medical Corporation UV cured gel and method of making
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9012506B2 (en) * 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US20090011116A1 (en) * 2004-09-28 2009-01-08 Atrium Medical Corporation Reducing template with coating receptacle containing a medical device to be coated
US7166680B2 (en) * 2004-10-06 2007-01-23 Advanced Cardiovascular Systems, Inc. Blends of poly(ester amide) polymers
US9107850B2 (en) 2004-10-25 2015-08-18 Celonova Biosciences, Inc. Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same
US9114162B2 (en) 2004-10-25 2015-08-25 Celonova Biosciences, Inc. Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same
US20060089485A1 (en) * 2004-10-27 2006-04-27 Desnoyer Jessica R End-capped poly(ester amide) copolymers
US8603634B2 (en) * 2004-10-27 2013-12-10 Abbott Cardiovascular Systems Inc. End-capped poly(ester amide) copolymers
US7390497B2 (en) * 2004-10-29 2008-06-24 Advanced Cardiovascular Systems, Inc. Poly(ester amide) filler blends for modulation of coating properties
US20060095122A1 (en) * 2004-10-29 2006-05-04 Advanced Cardiovascular Systems, Inc. Implantable devices comprising biologically absorbable star polymers and methods for fabricating the same
US7214759B2 (en) * 2004-11-24 2007-05-08 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on polyesters and methods for fabricating the same
US8609123B2 (en) * 2004-11-29 2013-12-17 Advanced Cardiovascular Systems, Inc. Derivatized poly(ester amide) as a biobeneficial coating
US7588642B1 (en) 2004-11-29 2009-09-15 Advanced Cardiovascular Systems, Inc. Abluminal stent coating apparatus and method using a brush assembly
US7892592B1 (en) 2004-11-30 2011-02-22 Advanced Cardiovascular Systems, Inc. Coating abluminal surfaces of stents and other implantable medical devices
US20060115449A1 (en) * 2004-11-30 2006-06-01 Advanced Cardiovascular Systems, Inc. Bioabsorbable, biobeneficial, tyrosine-based polymers for use in drug eluting stent coatings
US7604818B2 (en) 2004-12-22 2009-10-20 Advanced Cardiovascular Systems, Inc. Polymers of fluorinated monomers and hydrocarbon monomers
US7419504B2 (en) * 2004-12-27 2008-09-02 Advanced Cardiovascular Systems, Inc. Poly(ester amide) block copolymers
US8007775B2 (en) * 2004-12-30 2011-08-30 Advanced Cardiovascular Systems, Inc. Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same
US7202325B2 (en) * 2005-01-14 2007-04-10 Advanced Cardiovascular Systems, Inc. Poly(hydroxyalkanoate-co-ester amides) and agents for use with medical articles
EP3354265A1 (en) * 2005-03-22 2018-08-01 President and Fellows of Harvard College Treatment of solid tumors
US7795467B1 (en) 2005-04-26 2010-09-14 Advanced Cardiovascular Systems, Inc. Bioabsorbable, biobeneficial polyurethanes for use in medical devices
US8778375B2 (en) 2005-04-29 2014-07-15 Advanced Cardiovascular Systems, Inc. Amorphous poly(D,L-lactide) coating
US7622070B2 (en) * 2005-06-20 2009-11-24 Advanced Cardiovascular Systems, Inc. Method of manufacturing an implantable polymeric medical device
US7823533B2 (en) * 2005-06-30 2010-11-02 Advanced Cardiovascular Systems, Inc. Stent fixture and method for reducing coating defects
US8021676B2 (en) 2005-07-08 2011-09-20 Advanced Cardiovascular Systems, Inc. Functionalized chemically inert polymers for coatings
US7785647B2 (en) * 2005-07-25 2010-08-31 Advanced Cardiovascular Systems, Inc. Methods of providing antioxidants to a drug containing product
US7735449B1 (en) 2005-07-28 2010-06-15 Advanced Cardiovascular Systems, Inc. Stent fixture having rounded support structures and method for use thereof
US20070084144A1 (en) * 2005-10-14 2007-04-19 Atrium Medical Corporation Packaging and sterilization of medical devices
WO2007047781A3 (en) * 2005-10-15 2007-12-27 Atrium Medical Corp Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
US8051797B1 (en) * 2005-11-07 2011-11-08 Boston Scientific Scimed, Inc. Device to stabilize and align a pre-mounted stent
US20070128246A1 (en) * 2005-12-06 2007-06-07 Hossainy Syed F A Solventless method for forming a coating
US20070135909A1 (en) * 2005-12-08 2007-06-14 Desnoyer Jessica R Adhesion polymers to improve stent retention
US7976891B1 (en) 2005-12-16 2011-07-12 Advanced Cardiovascular Systems, Inc. Abluminal stent coating apparatus and method of using focused acoustic energy
US7867547B2 (en) 2005-12-19 2011-01-11 Advanced Cardiovascular Systems, Inc. Selectively coating luminal surfaces of stents
WO2007095584A3 (en) 2006-02-14 2009-05-22 Harvard College Histone Deacetylase Inhibitors
CA2642273C (en) 2006-02-14 2016-09-20 President And Fellows Of Harvard College Bifunctional histone deacetylase inhibitors
US20070196428A1 (en) * 2006-02-17 2007-08-23 Thierry Glauser Nitric oxide generating medical devices
US7601383B2 (en) * 2006-02-28 2009-10-13 Advanced Cardiovascular Systems, Inc. Coating construct containing poly (vinyl alcohol)
US7713637B2 (en) * 2006-03-03 2010-05-11 Advanced Cardiovascular Systems, Inc. Coating containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer
US20070231363A1 (en) * 2006-03-29 2007-10-04 Yung-Ming Chen Coatings formed from stimulus-sensitive material
US7691151B2 (en) 2006-03-31 2010-04-06 Spiration, Inc. Articulable Anchor
US20070259101A1 (en) * 2006-05-02 2007-11-08 Kleiner Lothar W Microporous coating on medical devices
US8304451B2 (en) * 2006-05-03 2012-11-06 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
US7985441B1 (en) 2006-05-04 2011-07-26 Yiwen Tang Purification of polymers for coating applications
US8069814B2 (en) 2006-05-04 2011-12-06 Advanced Cardiovascular Systems, Inc. Stent support devices
US8304012B2 (en) * 2006-05-04 2012-11-06 Advanced Cardiovascular Systems, Inc. Method for drying a stent
US7775178B2 (en) * 2006-05-26 2010-08-17 Advanced Cardiovascular Systems, Inc. Stent coating apparatus and method
US9561351B2 (en) * 2006-05-31 2017-02-07 Advanced Cardiovascular Systems, Inc. Drug delivery spiral coil construct
US8568764B2 (en) * 2006-05-31 2013-10-29 Advanced Cardiovascular Systems, Inc. Methods of forming coating layers for medical devices utilizing flash vaporization
US8703167B2 (en) 2006-06-05 2014-04-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug
US20080124372A1 (en) * 2006-06-06 2008-05-29 Hossainy Syed F A Morphology profiles for control of agent release rates from polymer matrices
US20070286882A1 (en) * 2006-06-09 2007-12-13 Yiwen Tang Solvent systems for coating medical devices
US8778376B2 (en) 2006-06-09 2014-07-15 Advanced Cardiovascular Systems, Inc. Copolymer comprising elastin pentapeptide block and hydrophilic block, and medical device and method of treating
US8603530B2 (en) 2006-06-14 2013-12-10 Abbott Cardiovascular Systems Inc. Nanoshell therapy
US8114150B2 (en) 2006-06-14 2012-02-14 Advanced Cardiovascular Systems, Inc. RGD peptide attached to bioabsorbable stents
US8048448B2 (en) 2006-06-15 2011-11-01 Abbott Cardiovascular Systems Inc. Nanoshells for drug delivery
US8017237B2 (en) 2006-06-23 2011-09-13 Abbott Cardiovascular Systems, Inc. Nanoshells on polymers
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
US9028859B2 (en) 2006-07-07 2015-05-12 Advanced Cardiovascular Systems, Inc. Phase-separated block copolymer coatings for implantable medical devices
US8685430B1 (en) 2006-07-14 2014-04-01 Abbott Cardiovascular Systems Inc. Tailored aliphatic polyesters for stent coatings
US8703169B1 (en) 2006-08-15 2014-04-22 Abbott Cardiovascular Systems Inc. Implantable device having a coating comprising carrageenan and a biostable polymer
CN101646468A (en) * 2006-10-10 2010-02-10 西洛诺瓦生物科学公司 Compositions and devices comrising silicone and specific polyphosphazenes
ES2378905T3 (en) * 2006-10-10 2012-04-19 Celonova Biosciences, Inc. Heart valve bioprotà © music with polyphosphazene
DE102006050221B3 (en) * 2006-10-12 2007-11-22 Translumina Gmbh Device for applying active substances on surfaces of medical implants, has retaining bracket at cartridge, where two cylindrical housing parts are provided, which are pluggable into each other and are sterilely sealed against each other
US9492596B2 (en) * 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
EP2083875B1 (en) * 2006-11-06 2013-03-27 Atrium Medical Corporation Coated surgical mesh
US8597673B2 (en) * 2006-12-13 2013-12-03 Advanced Cardiovascular Systems, Inc. Coating of fast absorption or dissolution
DE112008000881A5 (en) * 2007-01-21 2010-01-21 Hemoteq Ag Medical device for treating obstructions of body passages and prevent the threat of re-closures
US7815962B2 (en) * 2007-03-22 2010-10-19 Medtronic Vascular, Inc. Coated stent with evenly distributed therapeutic agent
US8147769B1 (en) 2007-05-16 2012-04-03 Abbott Cardiovascular Systems Inc. Stent and delivery system with reduced chemical degradation
US9056155B1 (en) 2007-05-29 2015-06-16 Abbott Cardiovascular Systems Inc. Coatings having an elastic primer layer
US8048441B2 (en) 2007-06-25 2011-11-01 Abbott Cardiovascular Systems, Inc. Nanobead releasing medical devices
US8109904B1 (en) 2007-06-25 2012-02-07 Abbott Cardiovascular Systems Inc. Drug delivery medical devices
US20090041845A1 (en) * 2007-08-08 2009-02-12 Lothar Walter Kleiner Implantable medical devices having thin absorbable coatings
US8043301B2 (en) * 2007-10-12 2011-10-25 Spiration, Inc. Valve loader method, system, and apparatus
CN101868199B (en) 2007-10-12 2016-04-06 斯波瑞申有限公司 Valve loader methods, systems, and devices
US20090110730A1 (en) * 2007-10-30 2009-04-30 Celonova Biosciences, Inc. Loadable Polymeric Particles for Marking or Masking Individuals and Methods of Preparing and Using the Same
US8164055B2 (en) * 2008-05-30 2012-04-24 Cordis Corporation Sample plate designs for MALDI and DESI for molecular imaging of coated medical devices on the applied biosystems Qstar/Voyager MALDI mass spectrometer
US8440716B2 (en) * 2008-07-23 2013-05-14 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
US9427423B2 (en) * 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
WO2011008393A3 (en) * 2009-07-17 2011-03-24 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
WO2011019393A3 (en) 2009-08-11 2011-06-16 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
US8567340B2 (en) * 2009-08-12 2013-10-29 Abbott Cardiovascular Systems Inc. System and method for coating a medical device
WO2011081712A1 (en) * 2009-12-31 2011-07-07 Boston Scientific Scimed, Inc. Cryo activated drug delivery and cutting balloons
KR101808874B1 (en) 2010-01-22 2018-01-18 에이스틸론 파마수티컬스 인코포레이티드 Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
US8685433B2 (en) 2010-03-31 2014-04-01 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
WO2012031236A1 (en) 2010-09-02 2012-03-08 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
CA2818125A1 (en) 2010-11-16 2012-05-24 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
DE102011002536A1 (en) * 2011-01-11 2012-07-12 Aesculap Ag Package containing a medical product for the treatment of human or animal cartilage damage
US8795241B2 (en) 2011-05-13 2014-08-05 Spiration, Inc. Deployment catheter
US8669360B2 (en) 2011-08-05 2014-03-11 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
US9056152B2 (en) 2011-08-25 2015-06-16 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
US9204982B2 (en) 2012-04-26 2015-12-08 Medtronic Vascular, Inc. Apparatus and methods for filling a drug eluting medical device via capillary action
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
US9364460B2 (en) 2012-09-19 2016-06-14 Douglas V. Faller PKC delta inhibitors for use as therapeutics
FR3027826A1 (en) * 2014-11-05 2016-05-06 Aerolia System and local area processing method
JP2018502097A (en) 2014-12-23 2018-01-25 ダナ ファーバー キャンサー インスティテュート,インコーポレイテッド Method of inducing targeted proteolysis by bifunctional molecule
WO2017024317A3 (en) 2015-08-06 2017-04-27 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597765A (en) * 1984-12-27 1986-07-01 American Medical Systems, Inc. Method and apparatus for packaging a fluid containing prosthesis
EP0565604B1 (en) * 1990-12-28 1999-07-28 Boston Scientific Corporation Catheter for drug delivery system
US5599352A (en) * 1992-03-19 1997-02-04 Medtronic, Inc. Method of making a drug eluting stent
DE69323619D1 (en) * 1992-03-23 1999-04-01 Bard Inc C R liquid collection
US5464650A (en) 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5637113A (en) 1994-12-13 1997-06-10 Advanced Cardiovascular Systems, Inc. Polymer film for wrapping a stent structure
US5605696A (en) 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
US5785715A (en) * 1995-12-07 1998-07-28 Schatz; Richard A. Retrieval shuttle
US5630830A (en) * 1996-04-10 1997-05-20 Medtronic, Inc. Device and method for mounting stents on delivery systems
US5833651A (en) * 1996-11-08 1998-11-10 Medtronic, Inc. Therapeutic intraluminal stents
US6203536B1 (en) * 1997-06-17 2001-03-20 Medtronic, Inc. Medical device for delivering a therapeutic substance and method therefor
US6009614A (en) * 1998-04-21 2000-01-04 Advanced Cardiovascular Systems, Inc. Stent crimping tool and method of use

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8702781B2 (en) 2001-12-03 2014-04-22 J.W. Medical Systems Ltd. Apparatus and methods for delivery of multiple distributed stents
US8956398B2 (en) 2001-12-03 2015-02-17 J.W. Medical Systems Ltd. Custom length stent apparatus
US9326876B2 (en) 2001-12-03 2016-05-03 J.W. Medical Systems Ltd. Apparatus and methods for delivery of multiple distributed stents
US20040098118A1 (en) * 2002-09-26 2004-05-20 Endovascular Devices, Inc. Apparatus and method for delivery of mitomycin through an eluting biocompatible implantable medical device
US7396538B2 (en) 2002-09-26 2008-07-08 Endovascular Devices, Inc. Apparatus and method for delivery of mitomycin through an eluting biocompatible implantable medical device
US20080161908A1 (en) * 2002-09-26 2008-07-03 Endovascular Devices, Inc. Apparatus and Method for Delivery of Mitomycin Through an Eluting Biocompatible Implantable Medical Device
US20070101933A1 (en) * 2002-09-27 2007-05-10 Surmodics, Inc. Method and Apparatus for Coating of Substrates
US7125577B2 (en) 2002-09-27 2006-10-24 Surmodics, Inc Method and apparatus for coating of substrates
US20060165872A1 (en) * 2002-09-27 2006-07-27 Chappa Ralph A Advanced coating apparatus and method
USRE46251E1 (en) 2002-09-27 2016-12-27 Surmodics, Inc. Advanced coating apparatus and method
USRE40722E1 (en) 2002-09-27 2009-06-09 Surmodics, Inc. Method and apparatus for coating of substrates
US20050158449A1 (en) * 2002-09-27 2005-07-21 Chappa Ralph A. Method and apparatus for coating of substrates
US7669548B2 (en) 2002-09-27 2010-03-02 Surmodics, Inc. Method and apparatus for coating of substrates
US7776382B2 (en) 2002-09-27 2010-08-17 Surmodics, Inc Advanced coating apparatus and method
US7533514B2 (en) * 2003-04-25 2009-05-19 Boston Scientific Scimed, Inc. Method and apparatus for automated handling of medical devices during manufacture
US20040215347A1 (en) * 2003-04-25 2004-10-28 Michael Hayes Method and apparatus for automated handling of medical devices during manufacture
US9566179B2 (en) 2003-12-23 2017-02-14 J.W. Medical Systems Ltd. Devices and methods for controlling and indicating the length of an interventional element
US8585747B2 (en) 2003-12-23 2013-11-19 J.W. Medical Systems Ltd. Devices and methods for controlling and indicating the length of an interventional element
US20090234428A1 (en) * 2004-06-28 2009-09-17 Xtent, Inc. Devices and methods for controlling expandable prostheses during deployment
US9700448B2 (en) 2004-06-28 2017-07-11 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
US8986362B2 (en) 2004-06-28 2015-03-24 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
US7958840B2 (en) 2004-10-27 2011-06-14 Surmodics, Inc. Method and apparatus for coating of substrates
US20060088653A1 (en) * 2004-10-27 2006-04-27 Chappa Ralph A Method and apparatus for coating of substrates
US8652198B2 (en) 2006-03-20 2014-02-18 J.W. Medical Systems Ltd. Apparatus and methods for deployment of linked prosthetic segments
US9883957B2 (en) 2006-03-20 2018-02-06 J.W. Medical Systems Ltd. Apparatus and methods for deployment of linked prosthetic segments
US20110093056A1 (en) * 2006-06-02 2011-04-21 Xtent, Inc. Use of Plasma in Formation of Biodegradable Stent Coating
US8980297B2 (en) 2007-02-20 2015-03-17 J.W. Medical Systems Ltd. Thermo-mechanically controlled implants and methods of use
US20110022148A1 (en) * 2007-02-20 2011-01-27 Xtent, Inc. Thermo-mechanically controlled implants and methods of use
US9457133B2 (en) 2007-02-20 2016-10-04 J.W. Medical Systems Ltd. Thermo-mechanically controlled implants and methods of use
US9339404B2 (en) 2007-03-22 2016-05-17 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
US9101503B2 (en) 2008-03-06 2015-08-11 J.W. Medical Systems Ltd. Apparatus having variable strut length and methods of use
US9364349B2 (en) 2008-04-24 2016-06-14 Surmodics, Inc. Coating application system with shaped mandrel
US9308355B2 (en) 2012-06-01 2016-04-12 Surmodies, Inc. Apparatus and methods for coating medical devices
US9623215B2 (en) 2012-06-01 2017-04-18 Surmodics, Inc. Apparatus and methods for coating medical devices
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
US9283350B2 (en) 2012-12-07 2016-03-15 Surmodics, Inc. Coating apparatus and methods

Also Published As

Publication number Publication date Type
WO2001024734A1 (en) 2001-04-12 application
US6203551B1 (en) 2001-03-20 grant
US6346110B2 (en) 2002-02-12 grant

Similar Documents

Publication Publication Date Title
US6120847A (en) Surface treatment method for stent coating
US6530951B1 (en) Silver implantable medical device
US6156373A (en) Medical device coating methods and devices
US6364856B1 (en) Medical device with sponge coating for controlled drug release
US7575593B2 (en) Implantable device with reservoirs for increased drug loading
US6273908B1 (en) Stents
US5609629A (en) Coated implantable medical device
US7083642B2 (en) Delivery of therapeutic capable agents
US6730064B2 (en) Coated implantable medical device
US6979348B2 (en) Reflowed drug-polymer coated stent and method thereof
EP1521603B1 (en) Coated medical device
US20040088038A1 (en) Porous metal for drug-loaded stents
US20070053952A1 (en) Nitric oxide-releasing polymers derived from modified polymers
US20050203605A1 (en) Radially crush-resistant stent
US20060212109A1 (en) Delivery of therapeutic capable agents
US5624411A (en) Intravascular stent and method
EP0875218A2 (en) Porous medicated stent
US6395326B1 (en) Apparatus and method for depositing a coating onto a surface of a prosthesis
US5342348A (en) Method and device for treating and enlarging body lumens
US7055237B2 (en) Method of forming a drug eluting stent
US20080140172A1 (en) Multi-Wall Expandable Device Capable Of Drug Delivery Related Applications
US6379382B1 (en) Stent having cover with drug delivery capability
US20040202692A1 (en) Implantable medical device and method for in situ selective modulation of agent delivery
US5824048A (en) Method for delivering a therapeutic substance to a body lumen
US7572245B2 (en) Application of a therapeutic substance to a tissue location using an expandable medical device

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12